Abstracts tagged "autoimmune diseases"

Abstract Number: 1391 • 2012 ACR/ARHP Annual Meeting
Anti-Ku Autoantibodies in Systemic Lupus Erythematosus Versus Autoimmune Myositis As Measured by a Novel Chemiluminescence Assay
Michael Mahler¹, Jason Wu², Magdalena Szmyrka-Kaczmarek³, Andreas Swart⁴, Marvin J. Fritzler⁵, Jean-Luc Senécal⁶ and John G. Hanly⁷, ¹Research, INOVA Diagnostics, San Diego, CA, ²Research, INOVA Diagnostics, San Diego, ³Rheumatology, Wroclaw Medical University, Wroclaw, Poland, ⁴Rheumatology clinic Neuss, Neuss, Germany, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ⁷Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada
Background/Purpose: Autoantibodies targeting Ku, an abundant nuclear protein with DNA helicase activity, have been reported in patients with systemic autoimmune rheumatic diseases. Little is known…
Abstract Number: 1308 • 2012 ACR/ARHP Annual Meeting
Opportunistic Infections in Patients with Rheumatoid Arthritis Treated with Rituximab : Data From the Autoimmunity and Rituximab Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Thomas Bardin³, Patrice Cacoub⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Bertrand Godeau⁹, Loic Guillevin¹⁰, Xavier X. Le Loet¹¹, Eric Hachulla¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Isabelle Pane¹⁵, Gabriel Baron¹⁶ and Xavier Mariette¹⁷, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Rheumatology, Hôpital Lariboisière, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁶Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁷Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁸Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁹Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹¹Rheumatology Department, CHU de ROUEN, Rouen, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rheumatology, CHU Hautepierre, Strasbourg, France, ¹⁵Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁶Epidemiology, Strasbourg, France, ¹⁷Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Therapy with biological agents may be associated with opportunistic infections (OIs). Data on the occurrence of OIs in patients with RA treated with rituximab…
Abstract Number: 2682 • 2012 ACR/ARHP Annual Meeting
Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Systemic Lupus Erythematosus
Tomohiro Koga¹, Kunihiro Ichinose², Masayuki Mizui³, José C. Crispín⁴ and George C. Tsokos⁴, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Division of Rheumatology, Department of Medicine,, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with SLE exhibit abnormal signaling upon TCR engagement and have an altered gene expression profile. Accordingly, the regulation of several transcription factors…
Abstract Number: 1079 • 2012 ACR/ARHP Annual Meeting
Polyclonal CD4⁺Foxp3⁺treg Cells Induce TGFb-Dependent Tolerogenic Dendritic Cells That Suppress Murine Lupus-Like Syndrome
Qin Lan¹ and Song G. Zheng², ¹Medicine, University of Southern California, Los Angeles, CA, ²Medicine, Keck School of Medicine of USC, Los Angeles, CA
Background/Purpose: Interplay between Foxp3+ regulatory T cells (Treg) and dendritic cells (DCs) maintains immunologic tolerance, but the effects of each cell on the other are…
Abstract Number: 936 • 2012 ACR/ARHP Annual Meeting
Autoimmune Diseases: Declining Mortality Between 1999 and 2008 However Continuing to be a Leading Cause of Death in Children-A 10-Year Retrospective Review
Eric Y. Yen¹ and Deborah K. McCurdy², ¹Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ²Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA
Background/Purpose: Autoimmune diseases are chronic illnesses that cause significant and chronic disability in children and may lead to death. Using mortality data from 1995, Walsh…
Abstract Number: 729 • 2012 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Underlie Racial Disparities in Lupus Nephritis-Induced End-Stage Renal Disease
Robert P. Kimberly¹, Barry I. Freedman², Carl D. Langfeld³, Devin Absher⁴, Kelly K. Andringa¹, Daniel Birmingham⁵, Elizabeth E. Brown⁶, Mary E. Comeau⁷, Karen H. Costenbader⁸, Lindsey A. Criswell⁹, Jeffrey C. Edberg¹⁰, John B. Harley¹¹, Judith A. James¹², Diane L. Kamen¹³, Joan T. Merrill¹⁴, Timothy B. Niewold¹⁵, Neha Patel¹⁶, Michelle Petri¹⁷, Rosalind Ramsey-Goldman¹⁸, Jane E. Salmon¹⁹, Mark Segal²⁰, Kathy Moser Sivils¹², Betty P. Tsao²¹, Bruce A. Julian¹ and Lupus Nephritis-ESRD Consortium²², ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ³Department of Biostatistics, Wake Forest University Health Sciences, Winston-Salem, NC, ⁴HudsonAlpha Institute for Biotechnology, Huntsville, AL, ⁵Medicine, Ohio State University Medical Center, Columbus, OH, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Wake Forest University Health Sciences, Winston-Salem, NC, ⁸Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹⁰Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ¹⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ¹⁶Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁹Rheumatology, Hospital for Special Surgery, New York, NY, ²⁰Medicine/Nephrology, University of Florida, Gainesville, FL, ²¹Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA, ²²Medicine, Birmingham, AL
Background/Purpose: The G1 and G2 coding variants in the apolipoprotein L1 gene (APOL1; G1: a compound missense allele (glycine-342/methionine-384) and G2: an in-frame deletion (deletion…
Abstract Number: 671 • 2012 ACR/ARHP Annual Meeting
Differences in the SLE Clinical Phenotype by Age of Diagnosis
T. Clark Powell¹, Elizabeth E. Brown on behalf of PROFILE², Gerald McGwin Jr.³, Luis M. Vila⁴, Yesenia C. Santiago-Casas⁴, Michelle Petri⁵, Rosalind Ramsey-Goldman⁶, John D. Reveille⁷, Sergio Duran⁸, Sergio M.A. Toloza⁹, Robin L. Brey¹⁰, Agustin Escalante¹¹, Randy Q. Cron¹², Robert P. Kimberly on behalf of PROFILE investigators¹³ and Graciela S. Alarcon¹⁴, ¹Medicine, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ⁸UIECD, Guadalajara, Mexico, Guadalajara, Mexico, ⁹Medicine, Hospital San Juan Bautista, Catamarca, Argentina, ¹⁰Medicine/Neurology, UTHSCSA, San Antonio, TX, ¹¹Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ¹²Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹³Clinical Immun & Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁴Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that is characterized by the presence of antinuclear autoantibodies, complement activation and the formation and…
Abstract Number: 678 • 2012 ACR/ARHP Annual Meeting
Estrogen Modulation of ZAS3 Is Mediated Through Estrogen Receptor α: An Underlying Mechanism of Gender-Bias in Systemic Lupus Erythematosus?
Nicholas Young¹, Alexandra Friedman², Lai-Chu Wu² and Wael N. Jarjour³, ¹Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Global population data has indicated that post-pubertal females have decreased rates of infectious diseases when compared to male counterparts and preadolescent or postmenopausal females. …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].